Latest news

Filter News Articles



Changes to REBIF listing on PBS

For Australians living with MS, REBIF will no longer be available on the Pharmaceutical Benefits Scheme (PBS) from 1 December 2022.

A decade in the making - $35 million dollars committed to research

We are excited and proud to announce that in the 2022/23 financial year, we are committing a further $5 million to neurological research!

A decade in the making - $34m committed to neurological research over the last decade.
Carers: The Unsung Heroes

Who might be these invisible heroes? These people are commonly known as ‘carers’, but ‘common’ and ‘ordinary’ they are not.

National Carers Week 2022.
Evusheld and the PBS

On 14 October 2022, the Pharmaceutical Benefits Advisory Committee (PBAC) recommended that Evusheld not be listed on the Pharmaceutical Benefits Scheme (PBS). However, this may be revised in the future and access will remain through current schemes.

Graphic that contains the text Medication Update and has images of pills, pill containers and a syringe.
An update about COVID-19

MSWA remains alert as we monitor the COVID-19 situation. This article provides a current updates and useful links for further information.

Jasmin's Story

"We are so grateful that MSWA looks after us"
44-year-old Jasmin Franklin was born with a rare condition called Klippel-Feil Syndrome. Remarkably, the diagnosis took 40 years to be found.

Watch Jasmin's incredible story…

Jasmin Franklin smiling for the camera while sitting in her wheelchair at an MSWA Centre.
Vumerity medication for relapsing-remitting MS, now approved under PBS

Vumerity® (diroximel fumarate) will be listed under the Pharmaceutical Benefit Scheme (PBS).

A graphic with the words Medication update written on it.
We thank Ros Harman

Ros Harman has announced her resignation from the MSWA Board after 18 years of service and valued contribution.

Professional photograph of Ros Harman.
Researcher in Focus: Professor Bruno Meloni

MSWA is proud to be funding this important West Australian research, led by Professor Bruni Meloni, that will potentially provide the first effective treatment to minimise the damage that occurs in the early phases of stroke.

Professor Bruno Meloni at the Perron Institute's labs.
Employment & Workplace Survey Results Released for World MS Day

The survey, where 1,748 Australians (of which 525 are living with MS) participated, revealed there is a disconnect between expectations and workplace realities for those with a health condition.

Briefcase icon on orange background.